By: Benzinga
UPDATE: Goldman Sachs Initiates Ariad Pharmaceuticals with Neutral Rating on Fair Valuation
In a report published Thursday, Goldman Sachs analyst Terence Flynn initiated coverage on Ariad Pharmaceuticals (NASDAQ: ARIA ) with a Neutral rating and $20.00 price target. In the report, Flynn noted, “ARIA is building a fully integrated, global biopharma company focused on targeted cancer therapies. The company obtained US regulatory
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here